Hoechst-Roussel intermittent claudication consumer ad
Executive Summary
The firm began running its revised institutional television ad campaign for intermittent claudication the week of Dec. 23. The ad is scheduled to run two-three weeks. A similar ad appears in print media, including the New York Times, USA Today, and TV Guide. The television ad is a revision of a previous Hoechst ad to which FDA objected. FDA asserted that the earlier ad's emphasis on availability of a drug (the unspecified Trental) constituted an advertisement for a specific Rx drug ("The Pink Sheet" Oct. 21, T&G-5).
You may also be interested in...
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.